🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,027 results for “ERA” Clear

  1. UI009

    United Therapeutics Europe Ltd

    Health

    phase 1 small molecule completed

    1 trial

  2. UI059

    United Therapeutics Europe Ltd

    Gastro-Intestinal Disorder

    phase 1 small molecule active

    1 trial

  3. UI059

    United Therapeutics Europe Ltd

    GERD

    phase 1 small molecule completed

    1 trial

  4. UI15AML055MT

    United Therapeutics Europe Ltd

    Healthy

    phase 1 small molecule completed

    1 trial

  5. UIC201602 and co-administration of UIC201601 and UIC201602

    United Therapeutics Europe Ltd

    Healthy

    phase 1 small molecule completed

    1 trial

  6. UKidney

    United Therapeutics Europe Ltd

    Kidney Failure, Chronic

    phase 1 other terminated

    1 trial

  7. UNEX-42

    United Therapeutics Europe Ltd

    Bronchopulmonary Dysplasia

    phase 1 mab terminated

    1 trial

  8. USB005 (aclerastide) Ophthalmic Solution

    United Therapeutics Europe Ltd

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  9. UT-15C

    United Therapeutics Europe Ltd

    Healthy

    phase 1 small molecule completed

    2 trials

  10. UT-15C SR (treprostinil diethanolamine)

    United Therapeutics Europe Ltd

    Pulmonary Arterial Hypertension

    phase 1 small molecule completed

    1 trial

  11. Ublituximab + TGR-1202

    TG THERAPEUTICS, INC.

    Chronic Lymphocytic Leukemia

    phase 1 small molecule completed

    1 trial

  12. Unesbulin

    PTC THERAPEUTICS, INC.

    Ovarian Cancer

    phase 1 small molecule completed

    1 trial

  13. V920

    United Therapeutics Europe Ltd

    Ebola Virus

    phase 1 mab completed

    1 trial

  14. VEGF Trap

    Regeneron UK Limited

    Macular Degeneration

    phase 1 small molecule completed

    1 trial

  15. VEGF Trap

    Regeneron UK Limited

    Neovascular Age Related Macular Degeneration

    phase 1 small molecule completed

    1 trial

  16. VEGF inhibitor PTC299

    PTC THERAPEUTICS, INC.

    Brain and Central Nervous System Tumors

    phase 1 small molecule completed

    1 trial

  17. VK0214

    Viking Therapeutics

    Adrenomyeloneuropathy Form (AMN) of X-linked Adrenoleukodystrophy (X-ALD)

    phase 1 small molecule completed

    1 trial

  18. VS-6766

    United Therapeutics Europe Ltd

    NSCLC

    phase 1 small molecule active

    1 trial

  19. VTP-1000

    Barinthus Biotherapeutics plc.

    Celiac Disease

    phase 1 mab active

    1 trial

  20. Vaccine/device combination for prevention of HFRS

    United Therapeutics Europe Ltd

    Hemorrhagic Fever With Renal Syndrome

    phase 1 mab completed

    1 trial

  21. Vadadustat

    Akebia Europe Limited

    Drug Interaction Potentiation

    phase 1 small molecule completed

    4 trials

  22. Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) 5 µg

    Hospital Authority, Hong Kong

    COVID-19 Pandemic

    phase 1 mab active

    1 trial

  23. Valemetostat Tosylate, DS-8201a, Datopotamab deruxtecan, Valemetostat Tosylate, Valemetostat Tosylate

    Daiichi Sankyo

    This study will be a Phase 1b, global, multicenter, open-label, 2-part study of valemetostat in combination with DXd ADCs. The Master Protocol study design contains independent subprotocols, which have been defined by treatment combination and subject population, as follows: Sub-protocol A: Valemetostat in combination with T-DXd in subjects with previously treated, unresectable and/or metastatic HER2-low (immunohistochemistry[IHC] 1+ or IHC 2+/in situ hybridization [ISH]-negative) BC; for details, see Sub-protocol A. Sub-protocol B: Valemetostat in combination with T-DXd in subjects with previously treated, advanced or metastatic HER2-positive gastric or GEJ adenocarcinoma; for details, see Sub-protocol B. Sub-protocol C: Valemetostat in combination with Dato-DXd in subjects with previously treated, locally advanced, unresectable, or metastatic non-squamous NSCLC with or without actionable genomic alteration(s); for details, see Sub-protocol C.

    phase 1 small molecule active

    1 trial

  24. Vancomycin Pre-Treatment

    Seres Therapeutics

    Allogeneic Hematopoietic Stem Cell Transplantation

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources